EBM BLS: 12 Months of Low-dose Apixaban Decreased Venous Thromboembolism Recurrence After 3 Months of Initial Treatment of a Triggered Venous Thromboembolism with Continuing Risk Factors
本文未提供摘要，请点击“查看全文”查看完整内容。